Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

Grandclément C. et al, (2024), Nat Commun, 15

The integrated on-chip isolation and detection of circulating tumour cells

Abusamra SM. et al, (2024), Sensors and Diagnostics

Antibody-based Imaging of Bioreductive Prodrug Release in Hypoxia

Tosun C. et al, (2023), JACS Au

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.

Pouleau B. et al, (2023), Blood, 142, 260 - 273

Adipocyte autophagy limits gut inflammation by controlling oxylipin and IL-10.

Richter FC. et al, (2023), EMBO J

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.

Agarwal G. et al, (2022), Cancers (Basel), 15

Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.

Leng H. et al, (2022), Nat Commun, 13

Multiple myeloma metabolism – a treasure trove of therapeutic targets?

Roman-Trufero M. et al, (2022), Frontiers in Immunology, 13

Editorial - Cancer and Bone special issue.

Edwards CM. and Drake MT., (2022), Bone, 158

Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.

Whitburn J. et al, (2022), Sci Adv, 8

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo

Gámez B. et al, (2022), Translational Oncology, 15, 101301 - 101301

Cell-extrinsic autophagy in mature adipocytes regulates anti-inflammatory response to intestinal tissue injury through lipid mobilization

Richter FC. et al, (2021)

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations.

Brown JE. et al, (2021), J Bone Oncol, 29

Myeloma and marrow adiposity: Unanswered questions and future directions.

Morris EV. and Edwards CM., (2021), Best Pract Res Clin Endocrinol Metab, 35

Advances in the molecular pharmacology of bone and cancer-related bone diseases.

Edwards CM. and Russell RGG., (2021), Br J Pharmacol, 178, 1889 - 1890

Morphogens and growth factor signalling in the myeloma bone-lining niche.

Morris EV. and Edwards CM., (2021), Cell Mol Life Sci

Biological relationship between bone and myeloma cells

Edwards CM. and Lawson MA., (2021), Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside, 1005 - 1017

Modeling the Human Bone-Tumor Niche: Reducing and Replacing the Need for Animal Data.

Rao SR. et al, (2020), JBMR Plus, 4

Myeloma cells down-regulate adiponectin in bone marrow adipocytes via TNF-alpha.

Morris EV. et al, (2019), J Bone Miner Res

Cholesterol promotes myeloma cell viability and increases bone marrow myeloma tumour burden in vivo

Beatriz G. et al, (2019), JOURNAL OF BONE AND MINERAL RESEARCH, 34, 198 - 198

Load More

1
2
3
4
5
6
7

Include forthcoming?